Leqvio FDA Approval

A3 Affordability - medical benefit coverage for LeqvioⓇ creates opportunity for 0 USD co-pay for 2/3 patients at launch PCSK9i abandonment rate by OOP cost¹ 41% Anticipated payer mix and co-pay for LeqvioⓇ at launch 66% Medicare Part B Commercial Anticipated co-pay 80% pay as % of eligible population 39% little as 0 USD Eligible patients pay 34% 22% Medicare 9% Advantage Other 8% 0 40-50 75-125 250-500 (Medicaid, federal) Co-pay (USD) 19% as little as 0 USD Varies; 0-20% co-insurance <10 USD $0 co-pay for 2/3 patients at launch PCSK9i - Proprotein convertase subtilisin/kexin type 9 inhibitor OOP - Out Of Pocket 1. LAAD; IQVIA US Market Access Strategy Consulting. 21 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation U NOVARTIS | Reimagining Medicine

View entire presentation